Cinven Capital Management (V) General Partner Ltd is selling 4.5 million of its shares in contract research organization Medpace Holdings Inc. at $55 apiece in a secondary offering.
Cincinnati-based Medpace will not receive any proceeds from the common stock sale being handled by investment funds affiliated with Cinven, which also granted the underwriter a 30-day option to buy up to an additional 675,000 common shares.
Parent company Cinven Ltd. is Medpace's largest shareholder with 10,399,997 shares outstanding, or about a 29.27% stake, as of June 14, according to S&P Global Market Intelligence data.
Morgan Stanley is acting as the sole book runner for the offering, expected to close on or about Aug 10.
Medpace provides clinical development services to biotechnology, pharmaceutical and medical device companies.